REVIEW ARTICLE

Fixed-dose combination therapy to improve hypertension treatment and control in Latin America

Silvia González-Gómez^a, Mayra Alejandra Meléndez-Gómez^a, Patricio López-Jaramillo^{a,b,c,*}

^a Research Institute, Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia

^b Instituto Masira, Facultad de Salud, Universidad de Santander (UDES), Colombia

^c Eugenio Espejo, Medical School, UTE, Quito, Ecuador

Received 1 February 2017; accepted 3 June 2017

KEYWORDS

Combined therapy;
Hypertension;
Medication
adherence;
Colombia

Abstract Hypertension is a major risk factor for cardiovascular disease. Its prevalence is increasing worldwide, and is more common in low and middle-income countries. The effectiveness of hypertension treatment is determined by health cost, awareness, and patients' compliance with the treatment. People worldwide with an adequate control of hypertension correspond to a very small percentage in low and medium income countries as the Latin America ones. Between the causes to explain these are the low availability, affordability and adherence to treatment with multiple pills. It has been proposed that fixed dose combination therapy could improve the availability, affordability, adherence and control of hypertension. This article aims to review the evidence, showing that fixed dose combination can improve adherence, decrease health cost and improve control of hypertension. Improvement in hypertension control with fixed dose combination could make an important contribution to efforts to fight against the global cardiovascular morbidity and mortality.

© 2017 Instituto Nacional de Cardiología Ignacio Chávez. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Terapia combinada;
Hipertensión;
Cumplimiento de la
medicación;
Colombia

Terapia de combinación a dosis fija para mejorar el tratamiento y el control de la hipertensión en América Latina

Resumen La hipertensión es un factor de riesgo importante para el desarrollo de enfermedades cardiovasculares. Su prevalencia está aumentando en todo el mundo, y es más común en los países de medianos a bajos ingresos. La eficacia del tratamiento de la hipertensión está determinada por el costo, el conocimiento y la adherencia de los pacientes con el tratamiento.

* Corresponding author at: Fundación Oftalmológica de Santander-FOSCAL, Calle 158 No 20 – 95 Cañaveral, Floridablanca, Colombia.
E-mail address: jplopezj@gmail.com (P. López-Jaramillo).

El control adecuado de la hipertensión corresponde a un porcentaje muy pequeño en países de medianos a bajos ingresos como los países de América Latina. Entre las causas para explicar esto se encuentran la baja disponibilidad, asequibilidad y adherencia al tratamiento con múltiples medicamentos antihipertensivos. Se ha propuesto que la terapia combinada a dosis fija podría mejorar la disponibilidad, asequibilidad, adherencia y control de la hipertensión. Este artículo tiene como objetivo revisar la evidencia que demuestra que la combinación de dosis fija puede mejorar la adherencia, disminuir los costos de salud y mejorar el control de la hipertensión. La mejoría en el control de la hipertensión con terapia de combinación a dosis fija podría aportar una importante contribución a los esfuerzos para combatir la morbilidad y la mortalidad cardiovascular a nivel mundial.

© 2017 Instituto Nacional de Cardiología Ignacio Chávez. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Hypertension is the most important risk factor for cardiovascular morbidity and mortality. It is estimated that hypertension is responsible for 9.4 million deaths per year¹ and has been associated with an increased risk of stroke, myocardial infarction, heart failure and renal failure.²⁻⁴

Recent projections suggest that the prevalence of hypertension will increase by 30% by 2025⁵ with low- and middle-income countries (LMICs) accounting for three quarters of the world's hypertensive population. Currently more than 80% of the attributable burden of blood pressure-related diseases are in LMICs.⁶ Recent meta-analyses showed that the prevalence of hypertension was the highest among Latin America and Caribbean populations. Moreover it is estimated that one of three individuals are hypertensive in these countries.⁷ Rapid lifestyle changes has led to an increase in several modifiable risk factors associated with hypertension such as sugar consumption, overweight, obesity and physical inactivity.⁸⁻¹⁰ In addition socioeconomic status (SES) influences hypertension rates with an increased prevalence among those with the lowest SES defined by income, occupation and education.¹¹⁻¹³ In Colombia, recently we reported that lower awareness, treatment and control of hypertension is observed between men younger than 50 years old, with low level of education, low income and living on rural areas.¹⁴ Different reason has been proposed to explain the effects of SES on blood pressure (BP) such as level of education,¹⁵ stress,¹⁶ less quality of life,¹⁷ working conditions,¹⁸ healthcare and medicine access.¹⁴

The Cardiovascular Risk Factor Multiple Evaluation in Latin America study (CARMELA) conducted in seven capital cities reported that 24.3–46.9% of patients were unaware of their hypertensive condition, more than half of those with hypertension were untreated, and only 12.0% were controlled, findings associated with the poor communication between health staff and the community.¹⁹ The average time taken to inform the patient is too lengthy and information regarding the implementation of healthy lifestyles and the need to take medicines to have a good control of hypertension and avoid complications is not well expressed.²⁰

Among the 23,578 patients from Latin-America who participated in the Population Urban and Rural Epidemiology (PURE) study,¹² the prevalence of hypertension (defined as

values of systolic blood pressure (SBP) ≥ 140 mmHg and diastolic blood pressure (DBP) ≥ 90 mmHg) was 50.8% in Argentina, 52.6% in Brazil, 46.7% in Chile and 37.5% in Colombia. Only 57% of the patients knew they had hypertension, 52.8% received treatment, but only 18.3% had adequate control of their high blood pressure (BP). In the results of the National Health Survey 2000 conducted in Mexico, the percentage of Mexicans with hypertension who were unaware of their condition was 61%, only 14.6% of hypertensive patients were controlled.⁸ These findings demonstrated the importance of improving awareness, diagnosis, and adequate treatment that allows a good control of hypertension (SBP < 140 mmHg).

Hypertension treatment in low income settings is expensive because is a chronic risk factor that requires life-long medication therapy and most of the hypertensive patients need on average at least two antihypertensive medications for adequate BP control.²¹ The PURE study demonstrated²² that the use of cardiovascular medications as drugs to treated hypertension is affected by the negative impact of a low percentage of availability and affordability of cardiovascular disease medicines, especially in LMICs, where the capacity to pay these class of medications could demand more that the half of the family income. Maybe these factors can explain the recent report of Mills et al.²³ who demonstrated that the age adjusted prevalence of hypertension increased from 2000 to 2010 in LMIC, whereas control of hypertension in men decreased and the awareness and treatment increased only slightly.

Fixed dose combination therapy comes as a possible solution to improve treatment and control of high blood pressure in LMICs due to a simplify algorithm of treatment and by increasing adherence. Moreover, the combination of two or more antihypertensive drugs in one pill acts with a synergistic mechanism reflecting better results controlling BP levels. This article aims to review the evidence that support this proposal.

Barriers for hypertension treatment in Latin America

Most of the countries of the Americas have non communicable disease prevention and control programs aligned

with global mandates, with a large emphasis on the control of hypertension.²⁴ Health policies aimed to promote lifestyle changes that improve blood pressure levels such as a healthier diet, low sodium intake, low alcohol intake, increased physical activity and cessation of smoking have lowered cardiovascular diseases (CVDs) in some wealthy regions of the world,^{25,26} but have had low impact in others, especially in LMIC.²⁷ Moreover, there are only few successful population-wide hypertension control programs and it has been shown that behavioral interventions to modify lifestyles are expensive, have low impact and are not sustainable over time.²⁸ Evidence suggests that education is the most important aspect of SES affecting hypertension control,^{14,29–31} but this factor is not easy to improve in a short time. Modifying lifestyles may be difficult to achieve for some patients, making necessary the use of multiple pharmacological compounds to improve BP levels. As reviewed before, in LMICs there are a limited use of antihypertensive medicines because of their poor availability, a lack of affordability, poor prescription and a lack of patient adherence.¹¹ So, if we want to reach the 25 × 25 goal of the World Health Organization,³² the call to action of the Lancet Commission on Hypertension³³ and the 20X20 strategy of the Latin American Society of Hypertension,³⁴ together with programs to implement changes in life style, we also need to implement programs that allow the improvement of the prescription of medications to treat hypertension. This therapy must be of high quality, affordable, available, with simplified indications to the patients permitting to improve the adherence and the BP control.

Fixed dose combination therapy for hypertensive treatment

A single dose of antihypertensive medication reduces SBP in average by 8–10 mmHg, but a largest effect can be achieved by increasing the dose of the medication.³⁵ Several studies have demonstrated that the combination of two agents from any two classes of antihypertensive drugs increases the BP reduction significantly more than increasing one agent dose.³⁶ Moreover, there are other advantages of initiating treatment with combination therapy in patients with high cardiovascular risk because there is a greater probability of achieving the target BP, and this lowers the probability of discouraging patient adherence with a multidrug therapy. Indeed, a survey showed that patients receiving combination therapy had a lower drop-out rate than patients with monotherapy.³⁷ European guidelines suggested fixed dose combination therapy over single drug therapy for hypertension treatment due to a higher compliance too.³⁸ The European experts noticed further advantage between physiological and pharmacological synergies among different classes of agents that may not only promote a greater BP reduction but also cause fewer side effects than a single agent.

The 2013 Latin America Society of Hypertension (LASH) consensus confirmed previous recommendations about hypertension treatment and highlighted the fact that diuretics, beta-blockers, calcium antagonists, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) are all suitable for the initiation and

maintenance of antihypertensive treatment.³⁹ This consensus favors the use of combinations of two antihypertensive drugs at fixed doses in a single tablet, because reducing the number of pills to be taken daily improves adherence, and increases the rate of BP control.⁴⁰ This approach is now facilitated by the availability of different fixed-dose combinations of the same drugs, which minimizes one of its inconveniences, namely the inability to increase the dose of one drug independently of the other.^{39,41}

Clinical trials with fixed dose combination therapy

There is only indirect data available from randomized trials about fixed dose combination therapy for management of BP and cardiovascular outcomes. Among the trials using fixed dose combination therapy for hypertension, three studies compared two-drug combination in one arm versus one drug more placebo: the ADVANCE trial compared an ACE inhibitor plus a diuretic with a diuretic with placebo,⁴² FEVER compared a calcium antagonist plus a diuretic versus a diuretic plus placebo⁴³ and ACCOMPLISH compared an ACE inhibitor in combination with either a diuretic or a calcium antagonist.⁴⁴ In all other trials, treatment was initiated by monotherapy in either arm and another drug (and sometimes more than one drug) was added in some patients. In some trials, the second drug was chosen by the investigator among those not used in the other treatment arms, as in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) study.⁴⁵

In trials comparing different regimens, all combinations have been used in a larger or smaller proportion of patients, without major differences in benefits. The only exceptions are two trials in which a large proportion of patients received either an angiotensin receptor blocker-diuretic combination or a calcium antagonist-ACE inhibitor combination,^{46,47} both of which were superior to a beta-blocker-diuretic combination in reducing cardiovascular events. However, a beta-blocker-diuretic combination was as effective as other combinations in several other trials^{45,48–50} and more effective than placebo in three trials.^{51–53} However, the beta-blocker-diuretic combination appears to elicit more cases of new-onset diabetes in susceptible individuals, compared with other combinations.⁵⁴

The ACCOMPLISH trial directly compared two combinations in all patients,⁴⁴ it found significant superiority of an ACE inhibitor-calcium antagonist combination over the ACE inhibitor-diuretic combination in cardiovascular outcomes despite no BP difference between the two arms. These unexpected results deserve to be repeated, because trials comparing a calcium antagonist-based therapy with a diuretic-based therapy have never shown superiority of the calcium antagonist. Nonetheless, the possibility that ACCOMPLISH results may be due to a more effective reduction of central BP by the association of a renin-angiotensin system blocker with a calcium antagonist deserves to be investigated. All these trials proved the effectiveness of fixed dose combination in hypertension therapy and thus in cardiovascular outcomes. Some of these studies results are summarized in [Table 1](#).

Table 1 Major drug combinations used in trials of antihypertensive treatment.

Clinical trial	Intervention	Patients	SBP diff (mmHg)	Adherence	Outcomes
<i>ADVANCE trial</i> ⁴²	Fixed combination of Perindopril and indapamide or matching placebo	Patients with diabetes	−5.6	73%	−9% micro/macrovascular events ($p=0.04$) 18% reduction in the risk of death from cardiovascular disease
<i>FEVER</i> ⁴³	Low-dose hydrochlorothiazide plus low dose felodipine extended release compared to only low-dose hydrochlorothiazide	Hypertensive patients	−4.2	85.9%	−27% cardiovascular events ($p < 0.001$)
<i>ACCOMPLISH</i> ⁴⁴	Benazepril plus amlodipine or benazepril plus hydrochlorothiazide	Hypertensive patients with risk factors	−1	Benazepril/amlodipine: 71.2% Benazepril-hydrochlorothiazide: 68.8%	−21% cardiovascular events ($p < 0.001$)
<i>ALLHAT study</i> ⁴⁵	Chlorthalidone, 12.5–25 mg/d; amlodipine 2.5–10 mg/d; or lisinopril	Hypertensive patients with risk factors	−2/−1	Adherence decreased over time from about 92% at 1 year to 84% to 87% at 5 years in all 3 treatment groups	Not significant in cardiovascular events

SBP diff: systolic blood pressure difference.

Evidence has shown that any of the drug classes blocking the renin-angiotensin system (ACEi and ARBs) combined with a dihydropyridine CCB, or combined with a thiazide diuretic, should be considered the preferred combination to initiate antihypertensive treatment for most patients, particularly in fixed-dose combination. Therefore, the selection of the individual components in each combination may be based mainly on the capacity of obtaining the lowest prizes of the original molecules in the different countries of Latin America.

In the review of Bautista et al.,⁵⁵ it was calculated that if in Latin-America a fixed dose combination therapy were given, the lifetime risk of cardiovascular events could be reduced by 15 percent in those in the high-risk group (those with a ten-year risk of cardiovascular disease greater than or equal to 15) or to those age fifty-five or older.

Recently, the results of the HOPE-3 study, in which Colombia participated including more than 1.500 patients, demonstrated that a combination therapy with a fixed dose of 16 mg/day of candesartan and 12.5 mg/of hydrochlorothiazide administered to individuals of intermediate-risk without CVD, with a SBP >144 mmHg (average 154 mmHg), produced an average decrease of 6/3 mmHg of SBP/DBP that was associated with a significant reduction of 27% in the relative risk of the composite outcome of cardiovascular death and non-fatal myocardial infarction and stroke (Fig. 1).⁵⁶

In participants with BP in the highest tertile who also received rosuvastatin (10 mg/day) and the two antihypertensive medications, there was an increase in the relative

Figure 1 Reduction of cardiovascular outcomes in the HOPE 3 study of combination therapy in the overall group and in tertile 3 of systolic blood pressure (>143 mmHg). HCTZ: hydrochlorothiazide, RRR: relative risk reduction, T3: tertile 3 of systolic blood pressure.

risk reduction to 40%.⁵⁷ Treatment adherence in HOPE-3 was high: 88.2% were taking the prescribed regimen at 1 year, 83.6% at 3 years, 75.0% at 5 years, and 76.8% at the end of the trial. Moreover, HOPE-3 confirmed the results reported by the Anglo-Scandinavian Cardiac Outcomes Trial,⁵⁸ showing a potential synergy between lipid-lowering and blood pressure lowering in the management of CVDs. Importantly, the HOPE-3 study demonstrated that the beneficial effects in reducing the cardiovascular events of a fixed dose of two antihypertensive drugs is observed only in people with a SBP >144 mmHg, but not in people with lower levels of SBP.⁵⁶ The study also showed that cardiovascular protection is achieved when SBP falls below 140 mmHg. The HOPE-3 results suggest that combination therapy with statin and two antihypertensive agents must be indicated for primary prevention for those individuals with a systolic blood pressure >140 mmHg, while the statin alone must be used in those individuals without high systolic BP because the protective effects of statin were independent of the levels of BP.⁵⁹

These results demonstrated for the first time that a combination of a statin with an ARB and a diuretic at low doses reduces LDL cholesterol, BP and cardiovascular events in patients with moderate risk and without cardiovascular disease. Moreover, the high adherence of these patients to the treatment support the proposal for the use of a combination of hypotensive drugs plus statin as an effective cardiovascular primary prevention strategy. However, the HOPE 3 study did not use the 3 medications in a single pill,⁵⁹ but currently several clinical trials are running to evaluate the efficacy of a polypill in primary and secondary prevention of CVDs.

All these studies proved that fixed dose combination therapy can control BP with an improvement of cardiovascular outcomes, the compliance was increased and the medications were well tolerated with few adverse events and non-relevant clinical changes in laboratory values. Thus, fixed dose combination could be a cheap solution improving the availability of medications, using generic medication of high quality for hypertension treatment in LMICs.

Fixed dose combination therapy cost

The mortality from CVDs has decreased in developed countries but it is increasing in LMIC.^{60,61} It is estimated that more than half of the reduction in mortality may be attributable to medical therapy when medications are accessible and affordable.²² Unfortunately, according to the World Health Organization in LMICs remains a low availability of effective pharmacological treatments in patients with hypertension and CVDs.⁶² The cost of cardiovascular drugs used in secondary prevention becomes a greater challenge within the health system, since a one-month supply of generic drugs is equivalent to 1.5–18.4 days of the minimum income in LMICs.⁶³

Inadequate health care systems are also implicated in poor hypertension control,⁵ and the low level of government investment in healthcare systems is associated with the inadequate use of cardiovascular drugs in individuals with clear indications for them, including antihypertensive medications.⁶⁴ In most Latin-American countries, more than 50% of the population have difficulties in accessing healthcare and to cover expenses related to health.⁶⁵ We have

identified that in Colombia the principal barriers to control of hypertension are related to the cost of transport to health care facilities and the copayment of medications.⁶⁶

In a meta-analysis in which was compared fixed dose combination therapy versus free drug combination therapy, it was found that the annual cost in 2009 for hypertension or cardio-vascular related cost were lower in patients with fixed dose combination therapy.⁶⁷ Fixed dose combination therapy has shown also to decrease the number of visits to the hospital, to decrease emergency department visits and hospitalizations,⁶⁸ and with an increased adherence to treatment. Furthermore, low adherence is correlated with a higher risk of cardiovascular events and CVDs, resulting in greater healthcare costs. Fixed combination therapy comes as a solution to reach an adequate compliance in hypertensive patients. In Latin America it has been estimated that fixed dose combination therapy would be cost-effective even in countries with low gross national income,⁵⁵ making affordable the treatment for hypertension. However, more studies are needed in Latin-America proving the benefits of fixed dose combination in BP control, CVDs prevention and healthcare cost.

Problems of fixed dose combination therapy

Although fixed dose combination therapy is an effective, easy and attractive hypertensive way of treatment, the strategy cannot be applied to all the patients because it lacks of flexibility and certain individuals may present with contraindications or adverse effects for one of the components.⁶⁹ Also with a fixed dose combination therapy some patients may be exposed to unnecessary therapy. Another problem with fixed dose combination are the patents for the components of a single pill with multiple antihypertensive medications. In a study conducted to assess the availability of free patent cardiovascular drugs, it was found that from 48 cardiovascular medication in Canada and United States, only 19 drugs (40%) were totally patent free.⁷⁰ This can be a strong barrier for the marketing and worldwide distribution of an antihypertensive fixed dose combination. Although some generics companies, are already producing generic medication of fixed dose combination based on the requirements of the regulatory authorities, providing a temporary solution. Another solution is that the pharmaceutical companies who own the original patents bring the pills with fixed dose combination to the market at an affordable price.

In conclusion, there is an increasing interest in the concept of prescribing a fixed dose of cardiovascular drugs such as antihypertensive medications. This is particularly interested in LMICs, where the burden of hypertension and cardiovascular diseases is high, resources for diagnostic are limited, and inexpensive and standardized treatments are more likely to be taken up in clinical practice than individualized therapeutic concepts. Fixed dose combination is effective controlling BP, because the administration of a single pill improves adherence, reduces CVDs and therefore decreases healthcare cost. However, there is the need to evaluate fixed dose combination in well-designed programs aimed to improve hypertension prevalence and cardiovascular prevention in Latin-America.

Funding

The authors confirm that no financial support was received for the research or writing of this article.

Conflict of interest

The authors have no conflicts of interest whatsoever to declare with any pharmaceutical or medical device Company.

References

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380:2224–60.
2. Howard G, Banach M, Cushman M, et al. Is blood pressure control for stroke prevention the correct goal? *Stroke*. 2015;46:1595–600.
3. Peters SAE, Huxley RR, Woodward M. Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals. *Stroke*. 2013;44:2394–401.
4. Baños-González M, Cantú-Brito C, Chiquete E, et al. Systolic blood pressure and functional outcome in patients with acute stroke: a Mexican registry of acute cerebrovascular disease (RENAMEVASC). *Arch Cardiol Mex*. 2011;81:169–75.
5. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. *Lancet*. 2005;365:217–23.
6. Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388:1459–544.
7. Sarki AM, Nduka CU, Stranges S, et al. Prevalence of hypertension in low- and middle-income countries. *Medicine (Baltimore)*. 2015;94:e1959.
8. Siervo M, Montagnese C, Mathers JC, et al. Sugar consumption and global prevalence of obesity and hypertension: an ecological analysis. *Public Health Nutr*. 2014;17:587–96.
9. Velázquez-Monroy O, Rosas Peralta M, Lara Esqueda A, et al. Prevalence and interrelations of noncommunicable chronic diseases and cardiovascular risk factors in Mexico. Final outcomes from the National Health Survey 2000. *Arch Cardiol Mex*. 2003;73:62–77.
10. Meaney A, Ceballos-Reyes G, Gutiérrez-Salmeán G, et al. Cardiovascular risk factors in a Mexican middle-class urban population. The Lindavista Study. Baseline data. *Arch Cardiol Mex*. 2013;83:249–56.
11. Leng B, Jin Y, Li G, et al. Socioeconomic status and hypertension. *J Hypertens*. 2015;33:221–9.
12. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. *JAMA*. 2013;310:959.
13. Onal AE, Erbil S, Ozel S, et al. The prevalence of and risk factors for hypertension in adults living in Istanbul. *Blood Press*. 2004;13:31–6.
14. Camacho PA, Gomez-Arbelaes D, Molina DI, et al. Social disparities explain differences in hypertension prevalence, detection and control in Colombia. *J Hypertens*. 2016;34:2344–52.
15. Cipullo JP, Martin JFV, Ciorlia LA, et al. Hypertension prevalence and risk factors in a Brazilian urban population. *Arq Bras Cardiol*. 2010;94:519–26.
16. Silva LBE, Silva SSB, Marcílio AG, et al. Prevalência de hipertensão arterial em Adventistas do Sétimo Dia da capital e do interior paulista. *Arq Bras Cardiol*. 2012;98:329–37.
17. Pierin AMG, Jesus EDS, Augusto MAdO, et al. Variáveis biopsicossociais e atitudes frente ao tratamento influenciam a hipertensão complicada. *Arq Bras Cardiol*. 2010;95:648–54.
18. Giroto E, Andrade SMD, Cabrera MAS. Prevalência de obesidade abdominal em hipertensos cadastrados em uma Unidade de Saúde da Família. *Arq Bras Cardiol*. 2010;94:754–62.
19. Hernández-Hernández R, Silva H, Velasco M, et al. Hypertension in seven Latin American cities: the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study. *J Hypertens*. 2010;28:24–34.
20. Ordunez P, Martinez R, Niebyski ML, et al. Hypertension prevention and control in Latin America and the Caribbean. *J Clin Hypertens*. 2015;17:499–502.
21. Burnier M, Brown RE, Ong SH, et al. Issues in blood pressure control and the potential role of single-pill combination therapies. *Int J Clin Pract*. 2009;63:790–8.
22. Khatib R, McKee M, Shannon H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. *Lancet*. 2016;387:61–9.
23. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control clinical perspective. *Circulation*. 2016;134:441–50.
24. Adler AJ, Prabhakaran D, Bovet P, et al. Reducing cardiovascular mortality through prevention and management of raised blood pressure. *Glob Heart*. 2015;10:111–22.
25. Vartiainen E, Laatikainen T, Peltonen M, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. *Int J Epidemiol*. 2010;39:504–18.
26. Weinehall L, Hellsten G, Boman K, et al. Can a sustainable community intervention reduce the health gap? 10-Year evaluation of a Swedish community intervention program for the prevention of cardiovascular disease. *Scand J Public Health*. 2001;29:59–68.
27. Alwan A, MacLean DR, Riley LM, et al. Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries. *Lancet*. 2010;376:1861–8.
28. Ebrahim S, Beswick A, Burke M, et al. Multiple risk factor interventions for primary prevention of coronary heart disease. *Cochrane Database Syst Rev*. 2006;CD001561, <http://dx.doi.org/10.1002/14651858.CD001561.pub2>
29. Christiani Y, Byles JE, Tavener M, et al. Assessing socioeconomic inequalities of hypertension among women in Indonesia's major cities. *J Hum Hypertens*. 2015;29:683–8.
30. Cutler DM, Lleras-Muney A. Understanding differences in health behaviors by education. *J Health Econ*. 2010;29:1–28.
31. Erceg M, Ivcević-Uhernik A, Kern J, et al. Is there any association between blood pressure and education level? The CroHort study. *Coll Antropol*. 2012;36 Suppl. 1:125–9.
32. World Health Organization. NCD global monitoring framework; 2017. Available at: http://www.who.int/nmh/global_monitoring_framework/en/ [accessed 21.06.17].
33. Olsen MH, Angell SY, Asma S, et al. A call to action and a life-course strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. *Lancet*. 2016;388:2665–712.
34. Lopez-Jaramillo P, Molina DI. The 20×20 Latin American Society of Hypertension target. *J Hypertens*. 2015;33:189–90.
35. Law MR. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. *BMJ*. 2003;326:1427–30.

36. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med.* 2009;122:290–300.
37. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. *J Hypertens.* 2010;28:1584–90.
38. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Blood Press.* 2013;22:193–278.
39. López-Jaramillo P, Sánchez RA, Diaz M, et al. Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. *J Hypertens.* 2013;31:223–38.
40. Gupta AK, Arshad S, Compliance Poulter NR. Safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. *Hypertension.* 2010;55:399–407.
41. López-Jaramillo P, Coca A, Sánchez R, et al. Hypertension guidelines: is it time to reappraise blood pressure thresholds and targets? *Hypertension.* 2016;68:257–62.
42. Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet.* 2007;370:829–40.
43. Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. *J Hypertens.* 2005;23:2157–72.
44. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med.* 2008;359:2417–28.
45. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA.* 2002;288:2981–97.
46. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B). *Lancet.* 2005;366:895–906.
47. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet.* 2002;359:995–1003.
48. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. *Lancet.* 1999;353:611–6.
49. Hansson L, Lindholm LH, Ekblom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet.* 1999;354:1751–6.
50. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet.* 2000;356:359–65.
51. Group SCR. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. *Lancet.* 2005;366:1267–78.
52. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. *Br Med J (Clin Res Ed).* 1986;293:1145–51.
53. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). *Lancet.* 1991;338:1281–5.
54. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and anti-hypertensive drugs. *J Hypertens.* 2006;24:3–10.
55. Bautista LE, Vera-Cala LM, Ferrante D, et al. A polypill aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. *Health Aff.* 2013;32:155–64.
56. Lonn EM, Bosch J, López-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. *N Engl J Med.* 2016;374:2009–20.
57. Yusuf S, Lonn E, Pais P, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. *N Engl J Med.* 2016;374:2032–43.
58. Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. *Eur Heart J.* 2006;27:2982–8.
59. Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. *Circulation.* 2010;122:2078–88.
60. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. Geneva: Published by the World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization; 2011.
61. Rosas Peralta M, Lara Esqueda A, Pastelín Hernández G, et al. National Re-survey of Arterial Hypertension (RENAHTA). Mexican consolidation of the cardiovascular risk factors. National follow-up cohort. *Arch Cardiol Mex.* 2005;75:96–111.
62. Mendis S, Abegunde D, Yusuf S, et al. WHO study on Prevention of REcurrences of Myocardial Infarction and Stroke (WHO-PREMISE). *Bull World Health Organ.* 2005;83:820–9.
63. Mendis S. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. *Bull World Health Organ.* 2007;85:279–88.
64. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. *Lancet.* 2011;378:1231–43.
65. Sanchez RA, Ayala M, Baglivo H, et al. Latin American guidelines on hypertension*. *J Hypertens.* 2009;27:905–22.
66. Legido-Quigley H, Camacho Lopez PA, Balabanova D, et al. Patients' knowledge, attitudes, behaviour and health care experiences on the prevention, detection, management and control of hypertension in Colombia: a qualitative study. *PLOS ONE.* 2015;10:e0122112, 10.1371/journal.pone.0122112.
67. Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. *J Clin Hypertens.* 2011;13:898–909.
68. Hess G, Hill J, Lau H, et al. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. *P&T.* 2008;33:652–66.
69. Orloff DG. Fixed combination drugs for cardiovascular disease risk reduction: regulatory approach. *Am J Cardiol.* 2005;96:28–33.
70. Beall RF, Schwalm J-DR, Huffman MD, et al. Could patents interfere with the development of a cardiovascular polypill? *J Transl Med.* 2016;14:242.